FDA Responds to Regeneron's EYLEA HD Application for Extended Dosing Intervals

Tarrytown, Friday, 18 April 2025.
On 18 April 2025, Regeneron announced the FDA’s response to its EYLEA HD supplemental application. While safety and efficacy concerns were cleared, the proposal for extended dosing intervals was rejected.